


LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Sitagliptin** (DPP-4 inhibitors)
- Comparator (class): **Exenatide** (GLP-1 Receptor Agonists)
- Outcome: **Venous thromboembolic events**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	645,122	578,578	2,800	4.84
Merative CCAE	79,894	67,847	316	4.66
Merative MDCD	8,550	6,125	75	12.25
Merative MDCR	13,924	13,431	168	12.51
Optum Clinformatics	41,599	33,677	337	10.01
Optum EHR	65,870	30,162	240	7.96
Veterans Affairs	-	-	-	-

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

